EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Erste Group Bank Has Negative View of Pfizer FY2026 Earnings
Pfizer announces results across serotypes in Phase 2 study of 25vPnC
Bill Gates Faces Court Over Claims COVID Jabs Were 'Lethal Biological Weapons'
Appeals Court Throws Out Alex Berenson's Case Against Pfizer Executives
Pfizer (PFE) Lung Cancer Drug Shows Survival Benefit Despite Trial Failure
DZ BANK AG Reaffirms Their Buy Rating on arGEN X (0QW0)
Pfizer Sees Path Forward for Cancer Drug Despite Trial Failure
Pfizer And 2 Other AI Healthcare Stocks To Watch
4 High-Yield Dividends That Could Be Next on the Chopping Block
Pfizer (NYSE:PFE) Stock Jumps 1.8% - Here's What Happened - Stock Observer
Is Pfizer (PFE) Cheap As Its Enodia Deal Fuels Oncology Growth Hopes?
Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial
Pfizer (NYSE:PFE) Shares Down 1.3% - Should You Sell? - Daily Political
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
What is Erste Group Bank's Estimate for BMY FY2027 Earnings? - Stock Observer
Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial
Pfizer (NYSE:PFE) Shares Climb 1.8% - Still a Buy?
Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher
Summit County Public Health offering updated COVID-19 vaccines
Pfizer's High Dividend Yield May Be a Warning. Here's How Merck Compares - 24/7 Wall St.
Pfizer Inc. (NYSE:PFE) Stock Has Average Price Target of $28.72 According to Brokerages - Zolmax
Pfizer (PFE) Backs Sec61 Drug Hunt In New Research Collaboration
Pfizer (PFE) Signs New Drug Discovery Pact Focused On Sec61 Inhibitors
Multiple myeloma in the Netherlands: 35-year trends in incidence and survival
Small Cell Lung Cancer Pipeline Analysis 2026: Phase III and Phase II Assets, MOA Breakdown, and Route of Administration Trends | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca | ABNewswire
Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial
European Commission Approves KEYTRUDA® Plus Padcev® as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer | INN
Global Life Science Market Report 2026: Size, Trends and Forecast to 2030 | Secure $200.6B AI and Precision Medicine Upside with Johnson & Johnson, Roche, Pfizer, and AstraZeneca
Global and regional burden of measles and vaccine coverage among children under 5 years, 1990−2023: a Global Burden of Disease Study
Global, regional and national burden of pertussis in 1990-2023: a Global Burden of Disease study
Pfizer (NYSE:PFE) Stock Price Up 2.4% - Still a Buy?
Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2%
18,032 Pfizer Inc. $PFE Shares Bought by Bank Pictet & Cie Europe AG - Zolmax
Pfizer (NYSE:PFE) Sets New 12-Month High - Here's What Happened - Zolmax
Pfizer (NYSE:PFE) Sets New 1-Year High - Should You Buy?
What Pfizer Bulls Got Right
Reviewing Nexentis Technologies (NASDAQ:NXTS) and Pfizer (NYSE:PFE) - Zolmax
Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally?
Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors | Morningstar
5 Dividend Stocks for Investors Who Want Income Without the Market's Wild Swings
Prediction: Eli Lilly Stock Could Be a Long-Term Winner for Investors
Pfizer's Dividend Freeze Raises a Bigger Question About Its Cash Flow
Critical Analysis: Nexentis Technologies (NASDAQ:NXTS) versus Pfizer (NYSE:PFE) - Daily Political
Bristol Myers is Cheaper Than Pfizer, but Its 40% Earnings Jump Has a Catch
$50,000 in These 5 Dividend Stocks Could Pay You $2,700 a Year
Old Pfizer building to undergo repairs after columns buckle
Peripheral T-Cell Lymphoma Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2026-2036 | DelveInsight | ABNewswire
Rare prostate cancer histologies: detection, characteristics and treatment
Pfizer (PFE) Gets a Hold from Wells Fargo
Does Expanded Tukysa Approval Change The Bull Case For Pfizer (PFE)?
Pfizer or Kraft Heinz: Only One Gets My Dividend Dollars for the Next 10 Years
RBC Capital Reaffirms Their Hold Rating on Pfizer (PFE)
Health Care Down, But not by Much, Amid Defensive Bias - Health Care Roundup | Morningstar
Pfizer (NYSE:PFE) Shares Up 3% - Here's What Happened - Zolmax
Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know
Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Tukysa Approval Might Change The Case For Investing In Pfizer Stock (PFE)
Training the next generation of hepatologists for the cardiovascular-kidney-metabolic era
Ankylosing Spondylitis Market in the US to Grow from USD 3,366.93 Million at a CAGR of 8.36% Through 2032 | ABNewswire
Pharmaceutical Stocks To Keep An Eye On - October 15th - Zolmax
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
Big pharma is pouring billions into a new class of 'protein degrader' drugs | World News
Pfizer (NYSE:PFE) vs. Iterum Therapeutics (NASDAQ:ITRM) Head-To-Head Contrast - Markets Daily
Pfizer Inc. (PFE) - What Are Researchers Thinking About This Stock?
Combination therapy for BCG-unresponsive non-muscle-invasive bladder cancer: biological rationale and ongoing clinical strategies
Pfizer (NYSE:PFE) Stock Price Up 3% - Still a Buy?
Pfizer (NYSE:PFE) Hits New 12-Month High - What's Next?
Pfizer (NYSE:PFE) Stock Sees Unusually High Call Option Buying - Daily Political
Enodia and Pfizer collaborate on Sec61 inhibitors
5 Large-Cap Giants Paying 5% and Bigger Dividends to Be Bought and Held Forever
Pfizer (NYSE:PFE) Hits New 12-Month High - Still a Buy? - Daily Political
Pfizer (PFE) Signs Sec61 Drug Discovery Deal With A Research Partner
Pfizer partners with Enodia Therapeutics in $500m drug deal
Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial
Pfizer or Enbridge: Only One Gets My Dividend Dollars for the Next 10 Years
What Is Pfizer (PFE) Really Gaining From Its Sec61 Drug Discovery Deal?
Pfizer (PFE) Pays Out Over 226% of Earnings and Trades at 36.7x Trailing Against 9.8 Forward. What Is the Yield Telling You?
Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff
These 6 Dividend Stocks Look Like Income Bargains. Their Payout Ratios Say Otherwise
Pfizer FY2026 Earnings Forecast Raised by Erste Group Bank
Analysts Offer Insights on Healthcare Companies: Cogstate Ltd (OtherCOGZF) and Pfizer (PFE)
Type 2 Diabetes Market Set for Robust Growth Driven by Innovation and Pipeline Advances by 2036 - DelveInsight | Eli Lilly, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences, MediciNova | ABNewswire
New Evidence Raises Questions About Whether Military's COVID Vaccine Mandate Was Legal - Activist Post
How to Play PFE Stock as Pfizer Cuts 300 Jobs
Every Roth IRA Needs These High-Yield Dividend Stocks Over 6%
4 Blue Chip Giants That May Have to Cut Their Dividends
PFIZER News
CoreWeave Stock Forecast 2026–2030: Can CRWV Recover From the AI Debt Sell-Off?
Nebius Stock Price Prediction 2026–2030: Can AI Cloud Growth Justify the Cost?
Eli Lilly Stock Forecast 2026–2030: Can LLY Break Above $1,300 After Its 7% Five-Session Rally?
Is Oracle a Good Buy Right Now? Growth, Valuation and Long-Term Risks
Latest news
Show more
Microsoft Earnings Preview: Can Azure Growth Justify Rising AI Spending?
US Dollar Index Edges Lower Ahead of Fed Decision and Big Tech Earnings
Fed Rate Decision Preview: Will Kevin Warsh Hold Rates at 4% and Signal a December Hike?
Bitcoin Price Today Falls Below $80,000 as ETF Outflows and Liquidations Deepen the Sell-Off
Gold Price Forecast This Week: Can XAU/USD Reclaim $4,000 Before the Fed Decision?
